Notable 52-Week Highs and Lows 11/10: (KSS) (SODA) (BAC) High; (SEDG) (ANTH) (AVID) Low

November 10, 2016 3:16 PM EST

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

52-Week High:
  • $52.91. Kohl's Corp. reported Q3 EPS of $0.80, versus the analyst estimate of $0.70. Revenue for the quarter came in at $4.33 billion versus the consensus estimate of $4.33 billion. Comparable store sales fell 1.7 percent. Kohl's said it sees FY16 EPS of $3.80 - $4.00, versus the consensus of $3.87.

  • SodaStream (Nasdaq: SODA) $32.48. SodaStream reported Q3 EPS of $0.69, versus the analyst estimate of $0.23. Revenue for the quarter came in at $124.2 million versus the consensus estimate of $115.05 million.

  • Bank of America (NYSE: BAC) $18.99. BofA and banking peers surging higher following the election of Donald Trump as U.S. President earlier this week. It was largely expected that Clinton would clamp down on Wall Street, while the same can't be said for Trump.

  • MetLife, Inc. (NYSE: MET) $54.97. MetLife announced that its board of directors has approved a new $3 billion authorization for the company to repurchase its common stock.
52-Week Low:
  • SolarEdge Technologies (Nasdaq: SEDG) $11.35. SolarEdge Technologies reported Q1 EPS of $0.46, versus the analyst estimate of $0.44. Revenue for the quarter came in at $128.5 million versus the consensus estimate of $132.28 million. SolarEdge Technologies sees Q2 2017 revenue of $110-120 million, versus the consensus of $136.91 million.

  • Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) $1.72. Anthera Pharma announced that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks. Although 47% of patients in the blisibimod arm versus 42% of patients in the placebo arm achieved this endpoint, the difference was not statistically significant. The SRI is a composite index comprised of SELENA-SLEDAI, BILAG and Physician Global Assessment criteria. A SRI-6 response requires a decrease of at least 6 points in SELENA-SLEDAI. The magnitude of blisibimod treatment effects for other SLE Response (SRI-4, and SRI-8) also did not achieve statistical significance.

  • Avid Technology (Nasdaq: AVID) $4.49. Avid Technology reported Q3 EPS of $0.23, versus the analyst estimate of $0.42. Revenue for the quarter came in at $119 million versus the consensus estimate of $130.62 million. Avid Technology sees FY2016 revenue of $105 - $120 million, versus the consensus of $139.4 million. Avid Technology sees FY2016 revenue of $502 - $517 million, versus the consensus of $547.9 million.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Donald J. Trump, Bank of America

Add Your Comment